A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)

Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	A. V. Nersesov [verfasserIn] D. A. Kaibullaeva [verfasserIn] O. S. Vasnev [verfasserIn] L. K. Tashenova [verfasserIn] M. M. Sakhipov [verfasserIn] G. T. Berestimov [verfasserIn] G. A. Akhmetzhanova [verfasserIn] O. T. Ibekenov [verfasserIn] M. O. Doskhanov [verfasserIn] N. M. Zhumazhanov [verfasserIn] Zh. M. Balzhanov [verfasserIn] B. A. Aitmoldin [verfasserIn] E. A. Toleubaev [verfasserIn] E. M. Laryushina [verfasserIn] K. N. Zhumagulov [verfasserIn] G. N. Sobirova [verfasserIn] S. I. Umarova [verfasserIn] Yu. O. Shulpekova [verfasserIn] A. V. Okhlobystin [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2020

Schlagwörter:	gallbladder and sphincter of oddi dysfunction cholecystectomy biliary pain antispasmodics hymecromone

Übergeordnetes Werk:	In: Фармакоэкономика - IRBIS LLC, 2019, 13(2020), 2, Seite 205-219
Übergeordnetes Werk:	volume:13 ; year:2020 ; number:2 ; pages:205-219

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.17749/2070-4909/farmakoekonomika.2020.036

Katalog-ID:	DOAJ027582051

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ027582051
003	DE-627
005	20230410103218.0
007	cr uuu---uuuuu
008	230226s2020 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.17749/2070-4909/farmakoekonomika.2020.036 \|2 doi
035			\|a (DE-627)DOAJ027582051
035			\|a (DE-599)DOAJ1c98362b00784b28bcfbfdfcd0789b1a
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RM1-950
050		0	\|a HB71-74
100	0		\|a A. V. Nersesov \|e verfasserin \|4 aut
245	1	2	\|a A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented.
650		4	\|a gallbladder and sphincter of oddi dysfunction
650		4	\|a cholecystectomy
650		4	\|a biliary pain
650		4	\|a antispasmodics
650		4	\|a hymecromone
653		0	\|a Therapeutics. Pharmacology
653		0	\|a Economics as a science
700	0		\|a D. A. Kaibullaeva \|e verfasserin \|4 aut
700	0		\|a O. S. Vasnev \|e verfasserin \|4 aut
700	0		\|a L. K. Tashenova \|e verfasserin \|4 aut
700	0		\|a M. M. Sakhipov \|e verfasserin \|4 aut
700	0		\|a G. T. Berestimov \|e verfasserin \|4 aut
700	0		\|a G. A. Akhmetzhanova \|e verfasserin \|4 aut
700	0		\|a O. T. Ibekenov \|e verfasserin \|4 aut
700	0		\|a M. O. Doskhanov \|e verfasserin \|4 aut
700	0		\|a N. M. Zhumazhanov \|e verfasserin \|4 aut
700	0		\|a Zh. M. Balzhanov \|e verfasserin \|4 aut
700	0		\|a B. A. Aitmoldin \|e verfasserin \|4 aut
700	0		\|a E. A. Toleubaev \|e verfasserin \|4 aut
700	0		\|a E. M. Laryushina \|e verfasserin \|4 aut
700	0		\|a K. N. Zhumagulov \|e verfasserin \|4 aut
700	0		\|a G. N. Sobirova \|e verfasserin \|4 aut
700	0		\|a S. I. Umarova \|e verfasserin \|4 aut
700	0		\|a Yu. O. Shulpekova \|e verfasserin \|4 aut
700	0		\|a A. V. Okhlobystin \|e verfasserin \|4 aut
773	0	8	\|i In \|t Фармакоэкономика \|d IRBIS LLC, 2019 \|g 13(2020), 2, Seite 205-219 \|w (DE-627)176061677X \|x 20704933 \|7 nnns
773	1	8	\|g volume:13 \|g year:2020 \|g number:2 \|g pages:205-219
856	4	0	\|u https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.036 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/1c98362b00784b28bcfbfdfcd0789b1a \|z kostenfrei
856	4	0	\|u https://www.pharmacoeconomics.ru/jour/article/view/392 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2070-4909 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2070-4933 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 13 \|j 2020 \|e 2 \|h 205-219

Indexfelder

author_variant	a v n avn d a k dak o s v osv l k t lkt m m s mms g t b gtb g a a gaa o t i oti m o d mod n m z nmz z m b zmb b a a baa e a t eat e m l eml k n z knz g n s gns s i u siu y o s yos a v o avo
matchkey_str	article:20704933:2020----::mdrcnetoopscoeytcoyydoeaeoteaeilotedioyorh
hierarchy_sort_str	2020
callnumber-subject-code	RM
publishDate	2020
allfields	10.17749/2070-4909/farmakoekonomika.2020.036 doi (DE-627)DOAJ027582051 (DE-599)DOAJ1c98362b00784b28bcfbfdfcd0789b1a DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 A. V. Nersesov verfasserin aut A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented. gallbladder and sphincter of oddi dysfunction cholecystectomy biliary pain antispasmodics hymecromone Therapeutics. Pharmacology Economics as a science D. A. Kaibullaeva verfasserin aut O. S. Vasnev verfasserin aut L. K. Tashenova verfasserin aut M. M. Sakhipov verfasserin aut G. T. Berestimov verfasserin aut G. A. Akhmetzhanova verfasserin aut O. T. Ibekenov verfasserin aut M. O. Doskhanov verfasserin aut N. M. Zhumazhanov verfasserin aut Zh. M. Balzhanov verfasserin aut B. A. Aitmoldin verfasserin aut E. A. Toleubaev verfasserin aut E. M. Laryushina verfasserin aut K. N. Zhumagulov verfasserin aut G. N. Sobirova verfasserin aut S. I. Umarova verfasserin aut Yu. O. Shulpekova verfasserin aut A. V. Okhlobystin verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 13(2020), 2, Seite 205-219 (DE-627)176061677X 20704933 nnns volume:13 year:2020 number:2 pages:205-219 https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.036 kostenfrei https://doaj.org/article/1c98362b00784b28bcfbfdfcd0789b1a kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/392 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2020 2 205-219
spelling	10.17749/2070-4909/farmakoekonomika.2020.036 doi (DE-627)DOAJ027582051 (DE-599)DOAJ1c98362b00784b28bcfbfdfcd0789b1a DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 A. V. Nersesov verfasserin aut A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented. gallbladder and sphincter of oddi dysfunction cholecystectomy biliary pain antispasmodics hymecromone Therapeutics. Pharmacology Economics as a science D. A. Kaibullaeva verfasserin aut O. S. Vasnev verfasserin aut L. K. Tashenova verfasserin aut M. M. Sakhipov verfasserin aut G. T. Berestimov verfasserin aut G. A. Akhmetzhanova verfasserin aut O. T. Ibekenov verfasserin aut M. O. Doskhanov verfasserin aut N. M. Zhumazhanov verfasserin aut Zh. M. Balzhanov verfasserin aut B. A. Aitmoldin verfasserin aut E. A. Toleubaev verfasserin aut E. M. Laryushina verfasserin aut K. N. Zhumagulov verfasserin aut G. N. Sobirova verfasserin aut S. I. Umarova verfasserin aut Yu. O. Shulpekova verfasserin aut A. V. Okhlobystin verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 13(2020), 2, Seite 205-219 (DE-627)176061677X 20704933 nnns volume:13 year:2020 number:2 pages:205-219 https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.036 kostenfrei https://doaj.org/article/1c98362b00784b28bcfbfdfcd0789b1a kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/392 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2020 2 205-219
allfields_unstemmed	10.17749/2070-4909/farmakoekonomika.2020.036 doi (DE-627)DOAJ027582051 (DE-599)DOAJ1c98362b00784b28bcfbfdfcd0789b1a DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 A. V. Nersesov verfasserin aut A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented. gallbladder and sphincter of oddi dysfunction cholecystectomy biliary pain antispasmodics hymecromone Therapeutics. Pharmacology Economics as a science D. A. Kaibullaeva verfasserin aut O. S. Vasnev verfasserin aut L. K. Tashenova verfasserin aut M. M. Sakhipov verfasserin aut G. T. Berestimov verfasserin aut G. A. Akhmetzhanova verfasserin aut O. T. Ibekenov verfasserin aut M. O. Doskhanov verfasserin aut N. M. Zhumazhanov verfasserin aut Zh. M. Balzhanov verfasserin aut B. A. Aitmoldin verfasserin aut E. A. Toleubaev verfasserin aut E. M. Laryushina verfasserin aut K. N. Zhumagulov verfasserin aut G. N. Sobirova verfasserin aut S. I. Umarova verfasserin aut Yu. O. Shulpekova verfasserin aut A. V. Okhlobystin verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 13(2020), 2, Seite 205-219 (DE-627)176061677X 20704933 nnns volume:13 year:2020 number:2 pages:205-219 https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.036 kostenfrei https://doaj.org/article/1c98362b00784b28bcfbfdfcd0789b1a kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/392 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2020 2 205-219
allfieldsGer	10.17749/2070-4909/farmakoekonomika.2020.036 doi (DE-627)DOAJ027582051 (DE-599)DOAJ1c98362b00784b28bcfbfdfcd0789b1a DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 A. V. Nersesov verfasserin aut A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented. gallbladder and sphincter of oddi dysfunction cholecystectomy biliary pain antispasmodics hymecromone Therapeutics. Pharmacology Economics as a science D. A. Kaibullaeva verfasserin aut O. S. Vasnev verfasserin aut L. K. Tashenova verfasserin aut M. M. Sakhipov verfasserin aut G. T. Berestimov verfasserin aut G. A. Akhmetzhanova verfasserin aut O. T. Ibekenov verfasserin aut M. O. Doskhanov verfasserin aut N. M. Zhumazhanov verfasserin aut Zh. M. Balzhanov verfasserin aut B. A. Aitmoldin verfasserin aut E. A. Toleubaev verfasserin aut E. M. Laryushina verfasserin aut K. N. Zhumagulov verfasserin aut G. N. Sobirova verfasserin aut S. I. Umarova verfasserin aut Yu. O. Shulpekova verfasserin aut A. V. Okhlobystin verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 13(2020), 2, Seite 205-219 (DE-627)176061677X 20704933 nnns volume:13 year:2020 number:2 pages:205-219 https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.036 kostenfrei https://doaj.org/article/1c98362b00784b28bcfbfdfcd0789b1a kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/392 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2020 2 205-219
allfieldsSound	10.17749/2070-4909/farmakoekonomika.2020.036 doi (DE-627)DOAJ027582051 (DE-599)DOAJ1c98362b00784b28bcfbfdfcd0789b1a DE-627 ger DE-627 rakwb rus RM1-950 HB71-74 A. V. Nersesov verfasserin aut A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented. gallbladder and sphincter of oddi dysfunction cholecystectomy biliary pain antispasmodics hymecromone Therapeutics. Pharmacology Economics as a science D. A. Kaibullaeva verfasserin aut O. S. Vasnev verfasserin aut L. K. Tashenova verfasserin aut M. M. Sakhipov verfasserin aut G. T. Berestimov verfasserin aut G. A. Akhmetzhanova verfasserin aut O. T. Ibekenov verfasserin aut M. O. Doskhanov verfasserin aut N. M. Zhumazhanov verfasserin aut Zh. M. Balzhanov verfasserin aut B. A. Aitmoldin verfasserin aut E. A. Toleubaev verfasserin aut E. M. Laryushina verfasserin aut K. N. Zhumagulov verfasserin aut G. N. Sobirova verfasserin aut S. I. Umarova verfasserin aut Yu. O. Shulpekova verfasserin aut A. V. Okhlobystin verfasserin aut In Фармакоэкономика IRBIS LLC, 2019 13(2020), 2, Seite 205-219 (DE-627)176061677X 20704933 nnns volume:13 year:2020 number:2 pages:205-219 https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.036 kostenfrei https://doaj.org/article/1c98362b00784b28bcfbfdfcd0789b1a kostenfrei https://www.pharmacoeconomics.ru/jour/article/view/392 kostenfrei https://doaj.org/toc/2070-4909 Journal toc kostenfrei https://doaj.org/toc/2070-4933 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2020 2 205-219
language	Russian
source	In Фармакоэкономика 13(2020), 2, Seite 205-219 volume:13 year:2020 number:2 pages:205-219
sourceStr	In Фармакоэкономика 13(2020), 2, Seite 205-219 volume:13 year:2020 number:2 pages:205-219
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	gallbladder and sphincter of oddi dysfunction cholecystectomy biliary pain antispasmodics hymecromone Therapeutics. Pharmacology Economics as a science
isfreeaccess_bool	true
container_title	Фармакоэкономика
authorswithroles_txt_mv	A. V. Nersesov @@aut@@ D. A. Kaibullaeva @@aut@@ O. S. Vasnev @@aut@@ L. K. Tashenova @@aut@@ M. M. Sakhipov @@aut@@ G. T. Berestimov @@aut@@ G. A. Akhmetzhanova @@aut@@ O. T. Ibekenov @@aut@@ M. O. Doskhanov @@aut@@ N. M. Zhumazhanov @@aut@@ Zh. M. Balzhanov @@aut@@ B. A. Aitmoldin @@aut@@ E. A. Toleubaev @@aut@@ E. M. Laryushina @@aut@@ K. N. Zhumagulov @@aut@@ G. N. Sobirova @@aut@@ S. I. Umarova @@aut@@ Yu. O. Shulpekova @@aut@@ A. V. Okhlobystin @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	176061677X
id	DOAJ027582051
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027582051</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410103218.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2020 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17749/2070-4909/farmakoekonomika.2020.036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027582051</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1c98362b00784b28bcfbfdfcd0789b1a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB71-74</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. V. Nersesov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gallbladder and sphincter of oddi dysfunction</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cholecystectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biliary pain</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antispasmodics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hymecromone</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Economics as a science</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. A. Kaibullaeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. S. Vasnev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. K. Tashenova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. M. Sakhipov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">G. T. Berestimov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">G. A. Akhmetzhanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. T. Ibekenov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. O. Doskhanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. M. Zhumazhanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zh. M. Balzhanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">B. A. Aitmoldin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. A. Toleubaev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. M. Laryushina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">K. N. Zhumagulov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">G. N. Sobirova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. I. Umarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu. O. Shulpekova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Okhlobystin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Фармакоэкономика</subfield><subfield code="d">IRBIS LLC, 2019</subfield><subfield code="g">13(2020), 2, Seite 205-219</subfield><subfield code="w">(DE-627)176061677X</subfield><subfield code="x">20704933</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:205-219</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.036</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1c98362b00784b28bcfbfdfcd0789b1a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.pharmacoeconomics.ru/jour/article/view/392</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4909</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4933</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">205-219</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	A. V. Nersesov
spellingShingle	A. V. Nersesov misc RM1-950 misc HB71-74 misc gallbladder and sphincter of oddi dysfunction misc cholecystectomy misc biliary pain misc antispasmodics misc hymecromone misc Therapeutics. Pharmacology misc Economics as a science A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)
authorStr	A. V. Nersesov
ppnlink_with_tag_str_mv	@@773@@(DE-627)176061677X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	20704933
topic_title	RM1-950 HB71-74 A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan) gallbladder and sphincter of oddi dysfunction cholecystectomy biliary pain antispasmodics hymecromone
topic	misc RM1-950 misc HB71-74 misc gallbladder and sphincter of oddi dysfunction misc cholecystectomy misc biliary pain misc antispasmodics misc hymecromone misc Therapeutics. Pharmacology misc Economics as a science
topic_unstemmed	misc RM1-950 misc HB71-74 misc gallbladder and sphincter of oddi dysfunction misc cholecystectomy misc biliary pain misc antispasmodics misc hymecromone misc Therapeutics. Pharmacology misc Economics as a science
topic_browse	misc RM1-950 misc HB71-74 misc gallbladder and sphincter of oddi dysfunction misc cholecystectomy misc biliary pain misc antispasmodics misc hymecromone misc Therapeutics. Pharmacology misc Economics as a science
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Фармакоэкономика
hierarchy_parent_id	176061677X
hierarchy_top_title	Фармакоэкономика
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)176061677X
title	A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)
ctrlnum	(DE-627)DOAJ027582051 (DE-599)DOAJ1c98362b00784b28bcfbfdfcd0789b1a
title_full	A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)
author_sort	A. V. Nersesov
journal	Фармакоэкономика
journalStr	Фармакоэкономика
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	205
author_browse	A. V. Nersesov D. A. Kaibullaeva O. S. Vasnev L. K. Tashenova M. M. Sakhipov G. T. Berestimov G. A. Akhmetzhanova O. T. Ibekenov M. O. Doskhanov N. M. Zhumazhanov Zh. M. Balzhanov B. A. Aitmoldin E. A. Toleubaev E. M. Laryushina K. N. Zhumagulov G. N. Sobirova S. I. Umarova Yu. O. Shulpekova A. V. Okhlobystin
container_volume	13
class	RM1-950 HB71-74
format_se	Elektronische Aufsätze
author-letter	A. V. Nersesov
doi_str_mv	10.17749/2070-4909/farmakoekonomika.2020.036
author2-role	verfasserin
title_sort	modern conception of postcholecystectomy syndrome (based on the materials of the advisory board held on may 4, 2019 in almaty, kazakhstan)
callnumber	RM1-950
title_auth	A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)
abstract	Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented.
abstractGer	Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented.
abstract_unstemmed	Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)
url	https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.036 https://doaj.org/article/1c98362b00784b28bcfbfdfcd0789b1a https://www.pharmacoeconomics.ru/jour/article/view/392 https://doaj.org/toc/2070-4909 https://doaj.org/toc/2070-4933
remote_bool	true
author2	D. A. Kaibullaeva O. S. Vasnev L. K. Tashenova M. M. Sakhipov G. T. Berestimov G. A. Akhmetzhanova O. T. Ibekenov M. O. Doskhanov N. M. Zhumazhanov Zh. M. Balzhanov B. A. Aitmoldin E. A. Toleubaev E. M. Laryushina K. N. Zhumagulov G. N. Sobirova S. I. Umarova Yu. O. Shulpekova A. V. Okhlobystin
author2Str	D. A. Kaibullaeva O. S. Vasnev L. K. Tashenova M. M. Sakhipov G. T. Berestimov G. A. Akhmetzhanova O. T. Ibekenov M. O. Doskhanov N. M. Zhumazhanov Zh. M. Balzhanov B. A. Aitmoldin E. A. Toleubaev E. M. Laryushina K. N. Zhumagulov G. N. Sobirova S. I. Umarova Yu. O. Shulpekova A. V. Okhlobystin
ppnlink	176061677X
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.17749/2070-4909/farmakoekonomika.2020.036
callnumber-a	RM1-950
up_date	2024-07-04T02:13:50.330Z
_version_	1803612827505655808
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027582051</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410103218.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2020 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17749/2070-4909/farmakoekonomika.2020.036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027582051</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1c98362b00784b28bcfbfdfcd0789b1a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB71-74</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. V. Nersesov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Gallstone disease is revealed in 10–20% of the population with a clear tendency to affect the younger population. In a clinically manifested course, cholecystectomy remains the treatment of choice. Symptoms and signs persist or even become more severe after gallbladder surgery in 10-15% of cases (“postcholecystectomy syndrome”). Postcholecystectomy syndrome includes heterogeneous disorders of liver, pancreas, duodenum, sphincter of Oddi, etc. that can be associated with errors or negative consequences of surgical intervention. Often, symptoms may persist because of previously unrecognized chronic diseases of neighboring organs. The spectrum of effective conservative measures is rather limited. The Advisory Board was held on May 4, 2019, in Almaty (Kazakhstan) to re-estimate the definitions and categories related to the issue of the postcholecystectomy syndrome and to develop the diagnostic and treatment algorithm for patients with the postcholecystectomy dysfunction of the sphincter of Oddi. The statements discussed by the interdisciplinary team of gastroenterologists and surgeons were addressed to general practitioners, therapists, gastroenterologists, and surgeons. The Advisory Board emphasized that organic and functional biliary diseases manifest mainly by biliary pain, main characteristics of which were defined in the Rome IV consensus based on the statistical analysis of a large pool of clinical data. For a more accurate bile duct system assessment and the exclusion of cholelithiasis, the examination algorithm was proposed, which included abdominal ultrasound investigation, endoscopic ultrasound investigation of the pancreatobiliary area, and magnetic resonance cholangiopancreatography. Diagnostic algorithm for differentiation of functional biliary disorders from organic gastrointestinal pathology was developed. Sphincter of Oddi dysfunction may be considered as a postcholecystectomy syndrome manifestation in 1.5-3% of cases. Apart from rational nutrition, conservative management of functional gastrointestinal diseases implies pharmacological therapy. The efficacy of non-steroidal anti-inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin, and hymecromone was demonstrated in previous studies. Papillosphincterotomy is not effective in relieving biliary pain in cases of the sphincter of Oddi dysfunction. The proposed algorithm for the management of patients with the postcholecystectomy syndrome was presented.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gallbladder and sphincter of oddi dysfunction</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cholecystectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biliary pain</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antispasmodics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hymecromone</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Economics as a science</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. A. Kaibullaeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. S. Vasnev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. K. Tashenova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. M. Sakhipov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">G. T. Berestimov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">G. A. Akhmetzhanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. T. Ibekenov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. O. Doskhanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. M. Zhumazhanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zh. M. Balzhanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">B. A. Aitmoldin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. A. Toleubaev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. M. Laryushina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">K. N. Zhumagulov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">G. N. Sobirova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. I. Umarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu. O. Shulpekova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Okhlobystin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Фармакоэкономика</subfield><subfield code="d">IRBIS LLC, 2019</subfield><subfield code="g">13(2020), 2, Seite 205-219</subfield><subfield code="w">(DE-627)176061677X</subfield><subfield code="x">20704933</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:205-219</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.036</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1c98362b00784b28bcfbfdfcd0789b1a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.pharmacoeconomics.ru/jour/article/view/392</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4909</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-4933</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">205-219</subfield></datafield></record></collection>
score	7.403078

Nicht das Richtige dabei?

Schreiben Sie uns!

A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?